Ibragimova, Khava I. E.
Geurts, Sandra M. E.
Croes, Sander
Erdkamp, Frans
Heijns, Joan B.
Tol, Jolien
Vriens, Birgit E. P. J.
Aaldering, Kirsten N. A.
Dercksen, Marcus W.
Pepels, Manon J. A. E.
Peters, Natascha A. J. B.
van de Winkel, Linda
Tilli, Dominique J. P.
Vriens, Ingeborg J. H.
de Boer, Maaike
Tjan-Heijnen, Vivianne C. G. http://orcid.org/0000-0002-3935-7440
Funding for this research was provided by:
Zorginstituut Nederland (80-82500-98-8003)
Novartis
Roche
Pfizer Pharmaceuticals
Eli Lilly and Company
Article History
Received: 19 January 2021
Accepted: 3 March 2021
First Online: 20 March 2021
Compliance with ethical standards
:
: Khava I.E. Ibragimova Netherlands Organization for Health Research and Development (ZonMw: 80–82500-98–8003); Novartis BV; Roche; Pfizer; Eli Lilly. Sandra M.E. Geurts Netherlands Organization for Health Research and Development (ZonMw: 80–82500-98–8003); Novartis BV; Roche; Pfizer; Eli Lilly. Dominique J.P. Tilli Netherlands Organization for Health Research and Development (ZonMw: 80–82500-98–8003); Novartis BV; Roche; Pfizer; Eli Lilly. Maaike de Boer Netherlands Organization for Health Research and Development (ZonMw: 80–82500-98–8003); Novartis BV; Roche; Pfizer; Eli Lilly. Vivianne C.G. Tjan-HeijnenNetherlands Organization for Health Research and Development (ZonMw: 80–82500-98–8003); Novartis BV; Roche; Pfizer; Eli Lilly. All remaining authors have declared no conflicts of interest.
: The Registry was approved and the need for informed consent waived by the Medical Research Ethics Committee of Maastricht University Medical Center (METC 15–4-239).